Survodutide Therapy: Complete Guide
Survodutide is an investigational dual agonist of the GLP-1 and glucagon receptors, developed by Boehringer Ingelheim with Zealand Pharma. Adding glucagon receptor activity to GLP-1 is intended to raise energy expenditure as well as suppress appetite, a different strategy from tirzepatide's GIP/GLP-1 combination. It is in phase 3 trials for obesity and has also been studied in MASH. It is not approved anywhere and cannot be legally prescribed or sold.
Fact-checking at PeptideProbe is editorial, not clinical. Our editors check claims, dosing figures, and trial results against primary sources; they are not licensed clinicians and do not provide medical review. Nothing here is medical advice — talk to a qualified healthcare provider before starting any therapy.
What is Survodutide?
Survodutide is an investigational dual agonist of the GLP-1 and glucagon receptors, developed by Boehringer Ingelheim with Zealand Pharma. Adding glucagon receptor activity to GLP-1 is intended to raise energy expenditure as well as suppress appetite, a different strategy from tirzepatide's GIP/GLP-1 combination. It is in phase 3 trials for obesity and has also been studied in MASH. It is not approved anywhere and cannot be legally prescribed or sold.
How Survodutide Works
Survodutide works through specific biological pathways to produce its therapeutic effects. Consult with a qualified provider for detailed information about how this peptide therapy works for your specific condition.
Benefits & Uses
Under investigation for weight reduction and for metabolic dysfunction-associated steatohepatitis. No benefit should be regarded as established until the phase 3 programme reports and regulators review it.
Clinical Evidence & Research
Clinical research on Survodutide continues to evolve. Survodutide has been studied in preclinical and clinical settings. Speak with your provider about the current evidence base.
Side Effects & Safety
Reported adverse effects in trials are predominantly gastrointestinal — nausea, vomiting and diarrhoea — consistent with the incretin class. The full safety profile is not yet established, which is the point of the trials still running.
Dosing & Administration
Dosing protocols for Survodutide should be determined by a qualified healthcare provider based on your individual health profile, treatment goals, and response to therapy. Self-dosing without medical supervision is not recommended.
Find Survodutide Providers Near You
Search our directory for qualified providers offering Survodutide therapy. Filter by location, telehealth, and more.
Browse ProvidersSurvodutide FAQ
Under investigation for weight reduction and for metabolic dysfunction-associated steatohepatitis. No benefit should be regarded as established until the phase 3 programme reports and regulators review it.
Costs vary by provider and location. Contact providers directly for current pricing.
Survodutide has an FDA status of "Research". It is currently used in research and clinical settings. Consult with a qualified provider about its regulatory status and appropriate use.
Reported adverse effects in trials are predominantly gastrointestinal — nausea, vomiting and diarrhoea — consistent with the incretin class. The full safety profile is not yet established, which is the point of the trials still running.
PeptideProbe lists 0 providers offering Survodutide therapy. Use our directory to search by location, filter by telehealth availability, and compare providers.
Related Peptides
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.